Abstract: The present invention relates to antibodies against the endothelin receptor subtype A, in particular monoclonal antibodies, fragments or derivatives thereof. The present invention also relates to the therapeutic or diagnostic use of this antibody or as a research tool in the field of cancers, in particular glioblastoma.

Abstract: The present invention relates to a microfluidic chip capable of attracting and trapping a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element, and at least one array of microchannels (2) arranged between the reservoir (1) and the external medium (3) of the chip and enabling the chemoattractant compound to pass towards said medium and the biological element present in said medium to pass towards the reservoir (1), characterized in that each microchannel is in the form of a harpoon comprising at least two arrows spaced apart longitudinally and directed towards the reservoir, in which each arrow comprises two branches each having a free end forming an acute angle of between 10° and 80°, and in which each arrow comprises two openings (7) communicating with a longitudinal part of the microchannel and having a width of between 5 ?m and 30 ?m.

Abstract: The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: —providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; —the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: —a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilization of the emulsion.

Abstract: A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

Abstract: An infusible three-dimensional network of crosslinked acrylic-type polymer fibers, where the diameter of the fibers is between 0.1 and 1.5 ?m, the size of the interstices between the fibers is between 0.1 and 50 ?m2 and the stiffness of the network includes an elastic modulus between 0.01 and 10,000 kPa.

Abstract: A novel method for synthesizing NCA compounds. Also, a new use of a peptide coupling agent. The method makes it possible to obtain NCA compounds from ?-amino-acids, under mild and non-racemic reaction conditions, and in the absence of constraining reagents of use, such as phosgene, which may lead to the formation of undesirable by-products.

Abstract: A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

Abstract: The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present invention relates to new peptides comprising an amino acid sequence LL-[X]n-LL, wherein X is selected from R, L and W, and n=10 to 12, and wherein [X]n comprises 4 R, 4 L and between 2 and 4 W, that may be used as cell-penetrating peptides. The present invention also relates to nanoparticles comprising a peptide of the invention and a cargo molecule and uses thereof.

Abstract: The present invention is drawn to a new diagnosis method and a calculator for predicting the risk of developing a breast late effect (BLE), which is defined as atrophic skin, telangiectasia, induration (fibrosis), necrosis or ulceration, in a subject after radiotherapy (RT), by using Radiation Induced late effect using T-Lymphocyte Apoptosis (RILA) and clinical parameters. The invention is also drawn to diagnosis kits for the implementation of the method and a nomogram.

Abstract: A method of selecting T cells with improved anti-cancer activity, the method including: a) quantifying glucose transporter 1 (GLUT1) expression level at the cell surface of a population of T cells by using a GLUT1 ligand, b) selecting T cells having a low GLUT1 expression level, wherein the T cells having a low GLUT1 expression level have improved anti-cancer activity. Also, a population of T cells with improved anti-cancer activity for use in the treatment of cancer, to the use of a GLUT1 ligand for selecting T cells with improved anti-cancer activity, and to the use of GLUT1 as a biomarker of the anti-cancer therapeutic efficacy of T cells.

Abstract: A sensor for photoacoustic spectroscopy including a support and a mechanical resonator fastened to the support, including at least one sensor element designed to be vibrated by an acoustic wave, and at least one first capacitive electrode mechanically coupled to the sensor element so as to be moved by the sensor element when it is vibrated; and at least one second capacitive electrode forming with the at least one first electrode, a capacitive sensor; the support facing the sensor element, an apertured part formed by one or more through-openings. Also provided is a detection and/or measurement device and method, for photoacoustic spectroscopy, using such a sensor.

Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.

Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.

Abstract: An active implantable medical device including, once implanted, a module external to the patient and a module inside the patient, the external module and the internal module being intended to transfer energy and data from one to the other. Also, a method for transferring energy and data, the method being implemented by the active implantable medical device.

Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.

Abstract: A method for manufacturing a part made of composite material includes forming a ceramic matrix phase in pores of a fibrous preform by pyrolysis of a cross-linked copolymer ceramic precursor, the cross-linked copolymer including a first precursor macromolecular chain of a first ceramic having free carbon, and a second precursor macromolecular chain of a second ceramic having free silicon, the first macromolecular chain being bonded to the second macromolecular chain by cross-linking bridges including a bonding structure of formula *1—X—*2; in this formula, X designates boron or aluminium, -*1 designates the bond to the first macromolecular chain and -*2 the bond to the second macromolecular chain.

Abstract: A method for manufacturing a part made of composite material in which an adhesion promoter is grafted to a coating present on the fibre surface as well as to a ceramic precursor resin. Afterwards, a ceramic matrix phase is formed in the porosity of the fibre preform by pyrolysis of the polymerised resin.

Abstract: A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.